10x Genomics, Inc. (FRA:1KJ)

Market Cap	2.16B +94.2%
Revenue (ttm)	547.49M +5.2%
Net Income	-37.09M
EPS	-0.30
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	31
Open	17.63
Previous Close	17.90
Day's Range	17.63 - 17.63
52-Week Range	6.12 - 19.96
Beta	n/a
RSI	55.77
Earnings Date	May 1, 2026

About 10x Genomics

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium p...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2012
• Employees: 1,178
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1KJ

Financial Performance

In 2025, 10x Genomics's revenue was $642.82 million, an increase of 5.25% compared to the previous year's $610.79 million. Losses were -$43.54 million, -76.16% less than in 2024.

Financial numbers in USD